DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All cause mortality · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bleeding (timing not specified) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major VTE events bilateral ascending venography1 · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in major VTE events bilateral ascending venography1 compared with low molecular weight heparins (low certainty).
1 finding from 1 review
All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).
1 finding from 1 review
Total Bleeding events · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in total Bleeding events compared with low molecular weight heparins (low certainty).
1 finding from 1 review
ALT >3 times the upper normal limit · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors may leads to lower ALT >3 times the upper normal limit compared with low molecular weight heparins (low certainty).
1 finding from 1 review
PE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in PE at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Intervention not reported
Heparin‐induced thrombocytopenia (HIT) · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower heparin‐induced thrombocytopenia (HIT) (low certainty).
1 finding from 1 review
Major VTE events in TKR combined doses bilateral ascending venography · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in major VTE events in TKR combined doses bilateral ascending venography compared with vitamin K antagonists (low certainty).
1 finding from 1 review
All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).
1 finding from 1 review
Total Bleeding events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in total Bleeding events in TKR combined doses compared with vitamin K antagonists (low certainty).
1 finding from 1 review